Literature DB >> 31646605

Editorial - Moving forward on the pathway of targeted immunotherapies for type 1 diabetes: the importance of disease heterogeneity.

M Infante1, C Ricordi.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31646605     DOI： 10.26355/eurrev_201910_19188

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN： 1128-3602            Impact factor:   3.507


× No keyword cloud information.
  3 in total

1.  Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial.

Authors:  Johnny Ludvigsson; Indusmita Routray; Sriramulu Elluru; Per Leanderson; Helena E Larsson; Björn Rathsman; Ragnar Hanås; Annelie Carlsson; Torben Ek; Ulf Samuelsson; Torun Torbjörnsdotter; Jan Åman; Eva Örtqvist; Karun Badwal; Craig Beam; Rosaura Casas
Journal:  Future Sci OA       Date:  2020-06-23

Review 2.  Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.

Authors:  Marco Infante; David A Baidal; Michael R Rickels; Andrea Fabbri; Jay S Skyler; Rodolfo Alejandro; Camillo Ricordi
Journal:  Artif Organs       Date:  2021-07-15       Impact factor: 2.663

3.  BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report.

Authors:  Marco Infante; Andrea Fabbri; Nathalia Padilla; Francesca Pacifici; Pasquale Di Perna; Laura Vitiello; Alessandra Feraco; Maria Giuliano; Marina Passeri; Massimiliano Caprio; Camillo Ricordi; David Della-Morte; Luigi Uccioli
Journal:  Vaccines (Basel)       Date:  2022-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.